TABLE 1.
Clinical and molecular characterization of the 5 clusters extracted by ConsensusClusterPlus
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Cluster 5 | |
|---|---|---|---|---|---|
| Histology | |||||
| AITL | 81 (93%) | 33 (32%) | 8 (25%) | 5 (8%) | 0 |
| ALCL ALK-neg | 3 (3.5%) | 6 (6%) | 7 (22%) | 6 (9.5%) | 47 (88%) |
| PTCL-NOS | 3 (3.5%) | 64 (62%) | 17 (53%) | 52 (82.5%) | 8 (12%) |
| Gender | |||||
| Female | 26 (37%) | 31 (41%) | 4 (33%) | 20 (41%) | 8 (26%) |
| Male | 45 (63%) | 43 (59%) | 8 (67%) | 28 (59%) | 22 (74%) |
| Age (Median) | 64 (33–87) | 62 (19–88) | 60 (35–97) | 62 (21–87) | 59 (31–80) |
| TET2 | |||||
| MUT | 26 (84%) | 19 (65%) | 0 (0%) | 6 (32%) | 0 |
| WT | 5 (16%) | 10 (35%) | 1 (100%) | 13 (68%) | 0 |
| DNMT3A | |||||
| MUT | 13 (42%) | 9 (31%) | 0 | 3 (16%) | 0 |
| WT | 18 (58%) | 20 (69%) | 1 (100%) | 16 (84%) | 0 |
| RHOA | |||||
| MUT | 23 (79%) | 15 (51%) | 0 | 2 (10.5%) | 0 |
| WT | 6 (21%) | 14 (49%) | 1 (100%) | 17 (89.5%) | 0 |
| IDH2 | |||||
| MUT | 16 (45%) | 1 (4%) | 0 | 1 (33%) | 0 |
| WT | 20 (55%) | 22 (96%) | 0 | 2 (67%) | 0 |